Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by floatinketuckyon Feb 23, 2022 11:51am
534 Views
Post# 34454039

Data to date going to the FDA

Data to date going to the FDAIf Theralase has toppling data current/material news. The may take that data to date to the FDA. Sometime Theralase cannot report due to regulatory restrictions.

Competitors will know this and report during the assessment period trying to inspire impatience.

Here is why I am considering this scenario...

They normally report
Cancer research updates and Cutting edge covid research updates in the quarterly.

However this time around they have PR the covid research
Theralase® Demonstrates Proof-of-Concept for Canadian-Made COVID-19 Vaccine
Toronto, Ontario – February 7, 2022


Ok then look to the insider buying...


The Corporate presentation is of no interest to the FDA.
The Company newsletter is of no interest to the FDA.

The FDA is interested in the data to date.

May 19, 2020Shawn Shirazi went on to say, "In a 3Q2019 conference call with the FDA, it was discussed and agreed between the FDA and the Company,
post receipt of the FDA IND authorization, based on the clinical study data collected to date.

It was further discussed and agreed that Theralase would potentially be eligible for Breakthrough Therapy Designation ("BTD") and/or Accelerated Approval (AA)

if Theralase can demonstrate clinically significant results (high safety profile and high efficacy response), similar to the safety and efficacy results observed in the Phase Ib NMIBC study (high safety profile and 67% CR) at an interim analysis of approximately 20 to 25 patients enrolled and successfully treated."

This is the link to the quarterly newsletters... Currently the public only has information on this study up to NOV 28 2021.

Link to TLTFF NEWSLETTERS



TLTFF long.


<< Previous
Bullboard Posts
Next >>